As the field of OMs expands, researchers continue to explore the effects of incretin mimetic‐based OMs acting on GLP‐1, glucose‐dependent insulinotropic polypeptide, and other hormone receptors, as well as novel agents that act on multiple receptors, in the hope of better targeting the complex endocrine‐based pathophysiology of obesity disease [34]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.